EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs
Panelists discuss how managing adverse events and selecting optimal treatment strategies remain key challenges in front-line EGFR-mutated, non–small cell lung cancer (mNSCLC) therapy, particularly when weighing the efficacy and toxicity profiles of available targeted therapies.
EP: 1.EGFR mNSCLC Front-Line: Treatment Options
EP: 2.EGFR mNSCLC: Challenges with Treatments in this Space
Now Viewing
EP: 3.EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs
EP: 4.PALOMA-3: Study Design and Baseline Characteristics
EP: 5.PALOMA-3: Key End Points: Pharmacokinetic and Secondary
EP: 6.PALOMA-3: Key Safety Data
EP: 7.PALOMA-3: Managing AEs
EP: 8.PALOMA-3: Clinical Implications
Recent Videos
Related Content
